Savient Announces Multiple Abstracts Related to KRYSTEXXA in the Treatment of Refractory Chronic Gout to be Presented at the 2012 ACR/ARHP Annual Meeting
BRIDGEWATER, N.J., Sept. 20, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA® (pegloticase) in the treatment of patients with Refractory Chronic Gout (RCG) will be presented at the 2012 ACR/ARHP Annual Meeting taking place in Washington D.C., from November 9-14, 2012.
Full text of the following accepted abstracts can be accessed by visiting the American College of Rheumatology website at www.rheumatology.org.
Complete Tophus Response in Patients with Chronic Gout
Initiating Pegloticase Treatment; Abstract #1913
Clinical Efficacy Outcomes with Up to 3 Years of Pegloticase
Treatment for Refractory Chronic Gout; Abstract #159
Improvements in Long-Term Health-Related Quality of Life in Chronic
Gout Patients Refractory to Conventional Therapies Treated with
Pegloticase: Results from Responder Cohort; Abstract #147
Patterns of Gout Treatment and Related Outcomes in US Community
Rheumatology Practices: the Relation Between Gout Flares, Time in
Treatment, Serum Uric Acid Level and Urate Lowering Therapy;
Abstract #1904
Pegloticase Long Term Safety: Data from the Open Label Extension
Trial; Abstract #160
Post?Marketing Safety Surveillance Data Reveals Patterns of Use for
Pegloticase in Refractory Chronic Gout; Abstract #169
Relative Risk of Infusion Reactions with KRYSTEXXA®
(pegloticase) from Post-Approval Safety Data: Results from Sept
2010 to June 2012; Abstract #170
Serum Uric Acid as a Biomarker for Mitigation of Infusion Reactions
in Patients Treated with Pegloticase for Refractory Chronic Gout;
Abstract #1916
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical
company focused on developing and commercializing KRYSTEXXA®
(pegloticase) for the treatment of chronic gout in adult patients
refractory to conventional therapy. Savient has exclusively
licensed worldwide rights to the technology related to KRYSTEXXA
and its uses from Duke University ("Duke") and Mountain View
Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant
uricase enzyme and MVP developed the PEGylation technology used in
the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S.
and foreign patents disclosing and claiming the licensed technology
and, in addition, Savient owns or co-owns U.S. and foreign patents
and patent applications, which collectively form a broad portfolio
of patents covering the composition, manufacture and methods of use
and administration of KRYSTEXXA. Savient is the manufacturer
of Oxandrin® (oxandrolone tablets, USP) CIII which is
distributed in the U.S. For more information, please visit the
Company's website at www.savient.com.
FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts included
in this press release are forward-looking statements that are
subject to certain risks, trends and uncertainties that could cause
actual results and achievements to differ materially from those
expressed in such statements. These risks, trends and uncertainties
are in some instances beyond our control. Words such as
"anticipate," "believe," "estimate," "expect," "intend," "plan,"
"will" and other similar expressions identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. In particular, any statements regarding
the safety and efficacy of KRYSTEXXA®, the potential to expand
the clinical utility of KRYSTEXXA, status of our KRYSTEXXA
marketing efforts in the US and additional plans related thereto
both in the US and ex-US, market demand and reimbursement for
KRYSTEXXA, our view of the refractory chronic gout (RCG) market
size in the US and ex-US, and our market expansion plans including
our MAA filing before the EMA are forward-looking statements. These
forward-looking statements involve substantial risks and
uncertainties and are based on our assessment and interpretation of
the currently available data and information, current expectations,
assumptions, estimates and projections about our business and the
biopharmaceutical and specialty pharmaceutical industries in which
we operate. Important factors that may affect our ability to
achieve the matters addressed in these forward-looking statements
include, but are not limited to, developments that may arise in the
litigation with Tang Capital; our ability to commercialize
KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than
we have anticipated; our ability to retain the personnel; our
reliance on third parties to manufacture KRYSTEXXA; competition
from existing therapies and therapies that are currently under
development, including therapies that are significantly less
expensive than KRYSTEXXA; our ability to gain market acceptance for
KRYSTEXXA among physicians, patients, health care payers and others
in the medical community; whether we are able to obtain financing,
if needed; economic, political and other risks associated with
foreign operations; risks of maintaining protection for our
intellectual property; risks of an adverse determination in
intellectual property litigation; and risks associated with
stringent government regulation of the biopharmaceutical industry
and other important factors set forth more fully in our reports
filed with the Securities and Exchange Commission, to which
investors are referred for further information. We may not actually
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements, which speak only as of the date
of publication of this press release. Actual results or events
could differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements that we make. Our
forward-looking statements do not reflect the potential impact of
any future acquisitions, mergers, dispositions, joint ventures or
investments that we may make. We do not have a policy of updating
or revising forward-looking statements and, except as required by
law, assume no obligation to update any forward-looking
statements.
SVNT-G
Contact:
Mary Coleman
Caitlyn Murphy
Savient Pharmaceuticals, Inc.
Burns McClellan
information@savient.com
cmurphy@burnsmc.com
(732) 418-9300
(212) 213-0006
SOURCE Savient Pharmaceuticals, Inc.
Web Site: http://www.savient.com
Posted: September 2012
